(Updated - December 17, 2025 10:40 AM EST)

Stifel analyst Paul Mattheis downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE